🔗 Share this article

While America undertakes sweeping changes to its vaccination guidelines, a particular individual has emerged somewhat surprisingly: Høeg, an American of Danish descent sports medicine doctor and public health researcher who first made her name by casting doubt on Covid vaccines in the global health crisis and has zeroed in on potential deaths after Covid immunization in her recent tenure at the Food and Drug Administration.

Proposed Changes to Pediatric Immunization Program

Health officials were set to unveil radical revisions to the pediatric vaccine schedule recently, bringing the US with the Danish vaccine program, according to reports – a major change that would put the US at odds with many the international standard with no evidence for benefit. The announcement has been pushed back until the new year.

Instead of the director of the vaccine center, Dr. Høeg is listed to address the audience at the gathering. She was just designated temporary leader of the FDA’s CDER, the fifth individual to head the center this year.

A New Direction at the FDA

This interim role may indicate a closer partnership between the drug and biologics centers as Høeg and Prasad solidify control at the agency – and it points to a greater focus upon reevaluating already-approved immunizations at the FDA.

Dr. Høeg has often pushed for ending some pediatric shot schedules in the US in order to be more similar to Denmark, a country with comprehensive healthcare and a number of inhabitants about the population of the state of Wisconsin.

To date statements, she has continued to focus on immunizations – traditionally the responsibility of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Doubts Over Expertise

Dr. Høeg has little discernible background in pharmaceutical research, approval processes or management, which has been typical for previous directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the FDA chief and CBER since earlier this year.

“It seems she lacks to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in running a major agency. She is not an expert in pharmaceutical oversight.”

Former heads of CBER would “grasp legal statutes and the underlying principles of medication creation”, said a former acting FDA commissioner. “Frankly, she doesn’t have the type of experience that previous people who headed CBER have had.”

CDER has an vast workload at the FDA, she emphasized.

“The public just zeroes in on the novel medication approvals, but the off-patent medication office clears a multitude of generic medications. There is also a biosimilars program, over-the-counter program and more, and all of those must be looked after,” Dr. Woodcock said. “The thing you overlook, that is precisely what that I always told people is going to cause problems.”

There is also, a major administrative aspect to the job, which supervises over 5,000 personnel. “It is a huge management job, if you perform it correctly,” the former official said.

Response and Controversial Policies

When asked about concerns about Høeg’s fitness for the role and whether this appointment indicates greater collaboration among FDA leaders on immunizations, a representative said that the “inquiries are based on inaccurate presumptions”.

“Her resume matches the functions of her role,” the official stated, pointing to the time Høeg spent advising the agency head on “medication safety and approval science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's recently launched expedited review system, a controversial rapid therapy clearance system that reportedly troubled her preceding directors. “By what process are these therapies being selected for this fast-track system? Who makes the calls?” Howard questioned. “There’s a lot of confidentiality happening at the regulatory body right now.”

In general, he said, “the Food and Drug Administration seems to be moving towards laxer regulations of most medications, with the exception of shots.”

Established Track Record on Vaccines

Regarding immunizations, Dr. Høeg has a more documented, if problematic, track record, critics observe. She authored a analysis using unconfirmed crowd-sourced reports to assess the rate of myocarditis after Covid immunization. She consulted for the state of Florida top health official Joseph Ladapo, who allegedly have modified findings to indicate COVID-19 vaccinations are pose a greater threat than they are.

Part of her “policy goals” for the current federal leadership encompassed altering regulations for new vaccines and halting “optional” vaccines, she said post-election on a online show. At the FDA, Høeg has according to sources suggested barring teenage boys from obtaining Covid vaccines.

“She is an thorough ideologue who begins with her beliefs and works backwards to fit the data in a highly deceptive, dishonest manner,” Dr. Howard argued.

Gaining Influence and a “Push for Payback”

Dr. Høeg joined other dissenters, {like|